Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Alector, Inc.
Deep Track Capital, LP has filed a Schedule 13G, reporting a beneficial ownership of more than 5% in Alector, Inc. This filing officially discloses the investor's significant stake in the company as of October 23, 2026.…more
Alector, Inc.
Alector, Inc. has finalized a public offering of 36,600,000 shares of common stock at a price of $2.05 per share, aiming to raise gross proceeds of $75.03 million. This offering will result in the dilution of existing shareholders, and the net proceeds are intended for general corporate purposes, including research, development, and strategic investments.…more
Alector, Inc.
Alector, Inc. has priced an underwritten offering of 36,600,000 shares of its common stock at $2.05 per share. The company expects to raise $75,030,000 in gross proceeds, which will be used for research and development, working capital, and strategic corporate purposes.…more
30 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
Alector Prices $75 Million Common Stock Offering
Alector has priced its underwritten offering of common stock at $2.05 per share, aiming to raise approximately $75 million in gross proceeds. The issuance of new shares may lead to shareholder dilution, which is typically viewed as a negative factor for the stock price.…more
●●●●●●●● ●●●●● ●●●●●●
Alector has priced a common stock offering of 36.6 million shares at $2.05 per share to raise approximately $75.03 million. This issuance is expected to dilute existing shareholders, which is typically viewed negatively for the stock price.…more
●●●●●●●● ●●●●● ●●●●●●
Alector will host a virtual R&D event to discuss its proprietary ABC blood-brain barrier platform and the progress of its pipeline programs. As the event focuses on sharing research updates without immediate financial impact, it is considered a neutral development.…more
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.